Two Sigma Investments LP Has $2.64 Million Holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Two Sigma Investments LP reduced its stake in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 22.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 353,954 shares of the company's stock after selling 103,098 shares during the period. Two Sigma Investments LP owned 0.52% of EyePoint Pharmaceuticals worth $2,637,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. RA Capital Management L.P. acquired a new stake in shares of EyePoint Pharmaceuticals in the fourth quarter valued at about $23,705,000. TCG Crossover Management LLC grew its position in shares of EyePoint Pharmaceuticals by 287.3% during the fourth quarter. TCG Crossover Management LLC now owns 3,572,335 shares of the company's stock worth $26,614,000 after acquiring an additional 2,650,000 shares during the last quarter. Adage Capital Partners GP L.L.C. increased its stake in shares of EyePoint Pharmaceuticals by 51.7% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 5,750,000 shares of the company's stock valued at $42,838,000 after purchasing an additional 1,958,580 shares during the period. Federated Hermes Inc. lifted its holdings in EyePoint Pharmaceuticals by 92.7% in the fourth quarter. Federated Hermes Inc. now owns 3,707,445 shares of the company's stock worth $27,620,000 after purchasing an additional 1,783,765 shares during the period. Finally, Suvretta Capital Management LLC increased its position in shares of EyePoint Pharmaceuticals by 31.1% during the 4th quarter. Suvretta Capital Management LLC now owns 6,783,091 shares of the company's stock valued at $50,534,000 after purchasing an additional 1,607,268 shares during the period. 99.41% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have issued reports on the company. Mizuho cut their price objective on EyePoint Pharmaceuticals from $30.00 to $26.00 and set an "outperform" rating on the stock in a report on Friday, May 16th. HC Wainwright reaffirmed a "buy" rating and set a $22.00 target price on shares of EyePoint Pharmaceuticals in a research report on Thursday, May 29th. Wall Street Zen raised shares of EyePoint Pharmaceuticals to a "sell" rating in a research report on Friday, March 14th. Finally, Chardan Capital dropped their price target on EyePoint Pharmaceuticals from $33.00 to $27.00 and set a "buy" rating for the company in a report on Thursday, May 8th. One equities research analyst has rated the stock with a sell rating and nine have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $25.38.

EyePoint Pharmaceuticals Stock Up 1.0%

Shares of NASDAQ:EYPT traded up $0.08 during midday trading on Wednesday, reaching $8.20. 635,138 shares of the company were exchanged, compared to its average volume of 821,537. EyePoint Pharmaceuticals, Inc. has a fifty-two week low of $3.91 and a fifty-two week high of $13.99. The firm has a market cap of $564.25 million, a PE ratio of -4.10 and a beta of 1.58. The stock has a fifty day simple moving average of $5.98 and a two-hundred day simple moving average of $6.93.

EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.65) EPS for the quarter, meeting analysts' consensus estimates of ($0.65). The company had revenue of $24.50 million during the quarter, compared to the consensus estimate of $8.84 million. EyePoint Pharmaceuticals had a negative net margin of 226.57% and a negative return on equity of 43.01%. As a group, analysts forecast that EyePoint Pharmaceuticals, Inc. will post -2.13 earnings per share for the current year.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.